drugset / Trial / NCT01124747

A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug

NCT01124747

Phase 1 Completed 12 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-label

Summary

The objective of this study is to assess the systemic disposition of ASP1585 after oral administration of 14C-labeled drug in healthy male subjects.

Timeline

Start
2010-04
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bixalomer Small molecule Oral

Indications

No indication recorded.